JPMorgan initiated coverage of CG Oncology (CGON) with an Overweight rating and $41 price target The company is developing the first oncolytic viral therapy to treat non-muscle invasive bladder cancer, the analyst tells investors in a research note. The firm believes CG’s lead asset, Cretostimogene, is well positioned as a “strong player in the evolving” bladder- sparing treatment landscape amid the shortage of Bacillus Calmette-Guerin.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- Biotech Alert: Searches spiking for these stocks today
- Buy Rating for CG Oncology, Inc. Driven by Cretostimogene’s Potential in Bladder Cancer Treatment Amid BCG Shortage
- CG Oncology Stock (CGON) Surges 25% As Cancer Drug Shows Remarkable Results
- CG Oncology Announces Promising Phase 3 Trial Results
- Promising Potential of CG Oncology’s Cretostimogene: A Buy Rating Justified by Superior Performance and Safety Profile